Related Experiment Video
Updated: Jul 27, 2025
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
Published on: November 20, 2011
Patient-Specific Microfluidic Cancer Spheroid Cultures for Testing Cancer Therapies
Daheui Choi1, Alan M Gonzalez-Suarez1, Daniel D Billadeau2
1Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Abstract:
The field of oncology increasingly focuses on strategies to predict effectiveness of a given therapy on a patient-by-patient basis. Such precision or personalized oncology has the potential of significantly extending patient survival time. Patient-derived organoids are seen as the main source of patient tumor tissue that may be used for therapy testing in personalized oncology. The gold standard approach for culturing cancer organoids is in standard multi-well plates coated with Matrigel. Despite their effectiveness, these standard organoid cultures have drawbacks, namely, requirement of a large starting cell population and polydispersity of cancer organoid sizes. The latter drawback makes it challenging to monitor and quantify changes in organoid size in response to therapy. Microfluidic devices with integrated arrays of microwells may be used to both decrease the amount of starting cellular material required to form organoids and to standardize organoid size to make therapy assessment easier. Herein, we describe methodology for making microfluidic device as well as for seeding patient-derived cancer cells, culturing organoids, and testing therapies using these devices.
Insights
Microfluidic devices offer a novel approach for personalized oncology, enabling efficient patient-derived organoid culture and therapy testing with standardized sizes and reduced cell requirements.
Area of Science:
- Oncology
- Biotechnology
- Bioengineering
Background:
- Precision oncology aims to personalize cancer therapy for improved patient outcomes.
- Patient-derived organoids are crucial for pre-clinical therapy testing.
- Current organoid culture methods in multi-well plates have limitations, including large cell input needs and variable organoid sizes.
Purpose of the Study:
- To present a methodology for utilizing microfluidic devices for patient-derived cancer organoid culture and therapy assessment.
- To address the limitations of traditional organoid culture methods.
Main Methods:
- Fabrication of microfluidic devices with integrated microwell arrays.
- Seeding of patient-derived cancer cells within the microfluidic device.
- Culture of cancer organoids in microwells.
- Assessment of therapeutic responses using the standardized organoids.
Main Results:
- Microfluidic devices reduce the required starting cell population for organoid formation.
- Standardized microwells lead to uniform organoid sizes, facilitating easier monitoring and quantification.
- The microfluidic platform enables efficient therapy testing on patient-derived organoids.
Conclusions:
- Microfluidic devices provide a standardized and efficient platform for patient-derived organoid culture.
- This technology supports advancements in personalized oncology by enabling robust therapy assessment.
- The developed methodology streamlines the process for personalized cancer treatment strategies.
